Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model

Kyriaki Dunussi-Joannopoulos, Howard J. Weinstein, Robert J. Arceci, James Croop

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model. Materials and Methods: Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells. Results: Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered >2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia. Conclusions: These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.

Original languageEnglish
Pages (from-to)536-540
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume19
Issue number6
DOIs
StatePublished - Nov 1997

Fingerprint

Granulocyte-Macrophage Colony-Stimulating Factor
Genetic Therapy
Vaccines
Cancer Vaccines
Immunity
Leukemia
Vaccination
T-Cell Antigen Receptor
Tumor Burden
Intravenous Injections
Neoplasms
Cytokines
Ligands

Keywords

  • AML
  • B7
  • Gene therapy
  • GM-CSF
  • Murine models

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. / Dunussi-Joannopoulos, Kyriaki; Weinstein, Howard J.; Arceci, Robert J.; Croop, James.

In: Journal of Pediatric Hematology/Oncology, Vol. 19, No. 6, 11.1997, p. 536-540.

Research output: Contribution to journalArticle

Dunussi-Joannopoulos, Kyriaki ; Weinstein, Howard J. ; Arceci, Robert J. ; Croop, James. / Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model. In: Journal of Pediatric Hematology/Oncology. 1997 ; Vol. 19, No. 6. pp. 536-540.
@article{00d6d3c333214f7f92bcffbfc6ffca20,
title = "Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model",
abstract = "Purpose: Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model. Materials and Methods: Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells. Results: Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered >2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia. Conclusions: These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.",
keywords = "AML, B7, Gene therapy, GM-CSF, Murine models",
author = "Kyriaki Dunussi-Joannopoulos and Weinstein, {Howard J.} and Arceci, {Robert J.} and James Croop",
year = "1997",
month = "11",
doi = "10.1097/00043426-199711000-00012",
language = "English",
volume = "19",
pages = "536--540",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model

AU - Dunussi-Joannopoulos, Kyriaki

AU - Weinstein, Howard J.

AU - Arceci, Robert J.

AU - Croop, James

PY - 1997/11

Y1 - 1997/11

N2 - Purpose: Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model. Materials and Methods: Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells. Results: Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered >2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia. Conclusions: These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.

AB - Purpose: Characterization of B7.1 and GM-CSF vaccines on the induction of anti-tumor immunity in a murine AML model. Materials and Methods: Primary AML cells were retrovirally transduced with the murine costimulatory molecule B7.1, a natural ligand for the T-cell receptors CD28 and CTLA-4, or the cytokine GM-CSF. Mice were vaccinated with irradiated AML cells expressing B7.1 or GM-CSF before or after inoculation of wild type AML cells. Results: Intravenous injection of irradiated B7.1 or GM-CSF expressing AML cells can provide long lasting systemic immunity against a subsequent challenge of wild type AML cells. Vaccination with irradiated B7.1 or GM-CSF expressing AML cells results in rejection of established leukemia when the vaccination occurs in the early stages of the disease. However, when the vaccines are administered >2 weeks after leukemic inoculation, only mice which receive the GM-CSF vaccine are cured of leukemia. Conclusions: These results suggest that tumor burden and vaccine efficiency are most likely to be the limiting factors in the curative potential of tumor vaccines. Novel approaches such as this experiment could provide improved therapeutic outcomes in patients with AML and other cancers.

KW - AML

KW - B7

KW - Gene therapy

KW - GM-CSF

KW - Murine models

UR - http://www.scopus.com/inward/record.url?scp=0031424377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031424377&partnerID=8YFLogxK

U2 - 10.1097/00043426-199711000-00012

DO - 10.1097/00043426-199711000-00012

M3 - Article

C2 - 9407942

AN - SCOPUS:0031424377

VL - 19

SP - 536

EP - 540

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 6

ER -